GALMED PHARMACEUTICALS LTD (GLMD) Stock Analyst Earnings Estimates
NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 470K | 1.09M 131.91% | 2.04M 87.16% | -100.00% | 14.725M | 43.722M 196.92% | ||||||||||
| EBITDA YoY % growth | -16.71M -54.29% | -12.12M 27.47% | -10.33M 14.77% | -20.4M -116.26% | -23.766M -35.05% | N/A -8.85% | N/A 46.38% | N/A 57.64% | N/A 17.05% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -16.88M -55.15% | -12.36M 26.78% | -10.72M 13.27% | -22.068M -108.77% | -28.231M -34.99% | -34.846M -8.84% | -19.24M 46.32% | -8.361M 57.56% | -10.841M 16.29% | -5.777M 7.86% | -5.834M -0.99% | -5.917M -1.42% | -31.886M -438.89% | -19.21M 39.76% | 4.62M 124.05% | |
| Operating Margin | -3,591.49% | -1,133.94% | -525.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -130.46% | 10.57% | |
| EPS YoY % growth | -268.20 -56.84% | -176.40 34.23% | -102.60 41.84% | -167.31 -70.18% | -228.77 -39.18% | -242.72 2.22% | -137.70 46.97% | -32.19 68.95% | -1.32 96.64% | -3.33 -152.71% | -0.87 73.93% | -0.50 42.35% | -1.85 -269.39% | 0.74 140.33% | 4.73 535.62% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.85 | -0.81 | -0.77 |
| Revenue Q2Q % growth | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -1.481M -21.40% | -1.398M 30.46% | -1.325M 19.41% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.62 | -0.91 | 0.29 | 31.70% |
| Q4 2023 Q2Q % growth | -11.76 34.67% | -3.92 | -7.84 | -200.25% |
| Q3 2023 Q2Q % growth | -2.88 92.38% | -3.30 | 0.42 | 12.85% |
| Q2 2023 Q2Q % growth | -11.40 57.78% | -4.16 | -7.24 | -173.93% |
| Q1 2023 Q2Q % growth | -13.08 69.72% | -18.36 | 5.28 | 28.76% |
| Q4 2022 Q2Q % growth | -18.00 66.67% | -25.70 | 7.70 | 29.97% |
| Q3 2022 Q2Q % growth | -37.80 32.26% | -30.29 | -7.51 | -24.78% |
| Q2 2022 Q2Q % growth | -27.00 54.55% | -43.33 | 16.33 | 37.69% |
| Q1 2022 Q2Q % growth | -43.20 36.84% | -58.75 | 15.55 | 26.47% |
| Q4 2021 Q2Q % growth | -54.00 37.50% | -55.54 | 1.54 | 2.77% |
| Q3 2021 Q2Q % growth | -55.80 3.13% | -65.73 | 9.93 | 15.11% |
| Q2 2021 Q2Q % growth | -59.40 -26.92% | -70.14 | 10.74 | 15.31% |
| Q1 2021 Q2Q % growth | -68.40 -31.03% | -70.69 | 2.29 | 3.23% |
| Q4 2020 Q2Q % growth | -86.40 -23.08% | -66.83 | -19.57 | -29.28% |
| Q3 2020 Q2Q % growth | -57.60 -52.38% | -55.08 | -2.52 | -4.58% |
| Q2 2020 Q2Q % growth | -46.80 -30.00% | -58.49 | 11.69 | 19.99% |
| Q1 2020 Q2Q % growth | -52.20 -70.59% | -67.24 | 15.04 | 22.37% |
| Q4 2019 Q2Q % growth | -70.20 | -63.24 | -6.96 | -11.01% |
| Q3 2019 Q2Q % growth | -37.80 | -53.45 | 15.65 | 29.28% |
| Q2 2019 Q2Q % growth | -36.00 | -40.60 | 4.60 | 11.32% |
| Q1 2019 Q2Q % growth | -30.60 | -36.95 | 6.35 | 17.18% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2019 Q2Q % growth | 63.75K | -63.75K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |